U.S. Vascular Grafts Market Size, Share & Trends Analysis Report By Product (Hemodialysis Access Grafts, Endovascular Stent Grafts), By Application (Cardiac Aneurysm, Kidney Failure, Vascular Occlusion), By Raw Material, And Segment- Industry Analysis, Sh
Description
The U.S. vascular grafts market size was estimated at USD 692.30 million in 2023 and is projected to hit around USD 1,349.18 million by 2033, growing at a CAGR of 6.9% during the forecast period from 2024 to 2033.
Key Takeaways:
The cardiac aneurysm market led the vascular grafts market with a revenue share of 51.9% in 2023.
The vascular occlusion segment is expected to witness the highest growth over the forecast period.
The polytetrafluoroethylene (PTFE) vascular grafts segment led the vascular grafts market with a revenue share of 45.12% in 2023.
The polyester vascular grafts segment is expected to witness considerable growth over the forecast period.
The endovascular stent grafts segment led the vascular grafts market with a revenue share of 64.27% in 2023.
The peripheral vascular grafts segment is expected to witness considerable growth over the forecast period.
Market Overview
The U.S. vascular grafts market has evolved into a vital pillar of cardiovascular and renal health care, underpinned by the rising prevalence of chronic diseases such as peripheral artery disease, coronary artery disease, and end-stage renal disease. A vascular graft is a medical device surgically implanted to replace, bypass, or repair blood vessels that are damaged or blocked. These devices are essential for ensuring adequate blood flow in patients where native blood vessels are no longer viable.
In the United States, cardiovascular diseases remain the leading cause of death, and a significant percentage of the population is either undergoing or at risk of requiring vascular surgeries. Concurrently, the increase in the aging population, high rates of obesity, diabetes, and sedentary lifestyles contribute to arterial degradation and increased incidences of aneurysms, occlusions, and renal dysfunction. The market also benefits from the country's highly developed healthcare infrastructure, innovation ecosystem, and favorable reimbursement policies.
Technological advancements in graft materials and surgical techniques have led to more minimally invasive options and better outcomes. Furthermore, the growing number of end-stage renal disease (ESRD) patients requiring hemodialysis access grafts has significantly propelled the demand for vascular grafts in nephrology. Leading manufacturers are increasingly focusing on hybrid and biologically engineered grafts that offer higher biocompatibility and longer patency, addressing longstanding concerns with infection and thrombosis.
Major Trends in the Market
Rising Adoption of Endovascular Stent Grafts: Minimally invasive endovascular aneurysm repair (EVAR) procedures are gaining popularity over traditional open surgeries.
Development of Biocompatible Hybrid Grafts: The industry is witnessing innovation in combining synthetic and biological elements for enhanced performance.
Increase in Hemodialysis Access Graft Demand: A growing population of chronic kidney disease (CKD) patients is driving demand for reliable vascular access devices.
Personalized and 3D-Printed Grafts: Precision medicine is influencing vascular graft design, with customized sizes and configurations becoming more feasible.
FDA Fast-Tracking Novel Graft Approvals: Regulatory bodies are expediting the approval of life-saving devices under breakthrough device designations.
Graft Integration with Drug-Eluting Technologies: Drug-coated grafts that minimize restenosis and thrombosis are emerging in clinical trials.
U.S. Vascular Grafts Market Report Scope
Report Attribute
Details
Market Size in 2024
USD 740.07 million
Market Size by 2033
USD 1,349.18 million
Growth Rate From 2024 to 2033
CAGR of 6.9%
Base Year
2023
Forecast Period
2024 to 2033
Segments Covered
Product, Application, Raw Material
Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)
Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled
Medtronic, Terumo Corporation, LeMaitre Vascular, Inc., Getinge AB, BD (Becton Dickinson), Abbott, B. Braun Melsungen AG., W. L. Gore and Associates, Inc., MicroPort Scientific Corporation, Endologix
Key Market Driver: High Prevalence of Cardiovascular and Renal Diseases
A fundamental driver for the U.S. vascular grafts market is the consistently high burden of cardiovascular and renal diseases across the population. According to the CDC, nearly 20 million Americans suffer from coronary artery disease, and over 800,000 Americans experience a heart attack annually. Vascular grafts are indispensable in managing these conditions, particularly when native blood vessels are no longer suitable for surgical use.
Simultaneously, over 786,000 Americans live with ESRD, many of whom undergo hemodialysis several times a week. For these patients, reliable access grafts are critical to sustaining life. The increasing incidence of risk factors such as hypertension, diabetes, and high cholesterol has contributed to the growing need for vascular intervention. As more individuals progress to stages requiring surgical solutions, the demand for vascular grafts across cardiovascular and renal applications continues to escalate.
Key Market Restraint: Risk of Graft-Related Infections and Complications
Despite technological innovations, the U.S. vascular grafts market faces challenges related to post-operative complications, particularly infections and graft thrombosis. Synthetic grafts, especially those used in long-term applications like hemodialysis access, are prone to bacterial colonization, leading to systemic infections and graft failure. These complications not only increase patient morbidity but also result in costly revisions or emergency interventions.
Additionally, mismatch in graft elasticity, improper healing, and immune reactions can contribute to limited patency rates, particularly in small-diameter grafts. While biological and hybrid grafts offer improved outcomes, they come with higher costs and logistical challenges in sourcing and storage. Concerns around long-term durability and performance in biologically engineered grafts have also posed caution among healthcare providers.
Key Market Opportunity: Biologically Engineered and Hybrid Vascular Grafts
As the industry shifts toward personalized medicine and biocompatibility, a major opportunity lies in the development and commercial expansion of biologically engineered and hybrid vascular grafts. These grafts aim to combine the strength and structure of synthetic materials with the healing potential and adaptability of biological tissues. For example, a graft composed of PTFE coated with autologous endothelial cells can reduce rejection rates and improve long-term patency.
Such next-generation grafts are also more suitable for younger patients or those requiring long-term implantation, as they adapt better to physiological conditions. Research collaborations between biotech companies and academic medical centers are driving innovation in this space. Companies focusing on tissue regeneration and stem cell applications are now entering the vascular graft market with promising solutions poised for FDA approvals.
Segments Insights:
By Product
Endovascular stent grafts dominated the U.S. vascular grafts market in 2024, primarily due to the growing preference for minimally invasive procedures. Endovascular aneurysm repair (EVAR) using stent grafts has revolutionized how abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) are treated. With less operative trauma, shorter hospital stays, and quicker recovery, stent grafts are increasingly chosen over open repair surgeries. Top-tier hospitals in the U.S. are now offering EVAR as a standard of care, particularly for older patients who are poor candidates for open surgery.
Hemodialysis access grafts are the fastest growing product segment, driven by the surge in ESRD patients requiring vascular access. Synthetic grafts, especially those made from PTFE, are widely used when autologous access is not feasible. Companies have also introduced self-sealing grafts and antimicrobial-coated variants to reduce complications. In 2024, multiple regional dialysis centers in the U.S. reported rising demand for graft placement surgeries, highlighting the need for durable and infection-resistant solutions.
By Application
Coronary artery disease (CAD) represented the dominant application segment, as coronary artery bypass grafting (CABG) remains a common surgical intervention for severe blockages. Vascular grafts are used to reroute blood flow around narrowed arteries, ensuring sufficient myocardial perfusion. The U.S. performs over 300,000 CABG procedures annually, making vascular grafts an integral part of cardiovascular surgery. The preference for synthetic and autograft options continues to vary based on patient profile and surgeon expertise.
Meanwhile, vascular occlusion is expected to be the fastest growing segment, attributed to the rising cases of peripheral artery disease (PAD), especially among diabetic and elderly populations. PAD results in poor limb perfusion, often requiring bypass grafts to avoid amputations. Hospitals across the Midwest and Southern U.S. have reported increased PAD-related surgeries, further expanding the market for lower limb vascular grafts and novel hybrid solutions that minimize thrombogenicity.
By Raw Material
Synthetic vascular grafts dominate the U.S. market, largely because of their long-standing use, reliability, and cost-effectiveness. Among these, PTFE grafts are most commonly used due to their non-thrombogenic surface and mechanical durability. They are standard in hemodialysis access, peripheral vascular repair, and certain cardiac procedures. Polyester grafts are also used widely in aortic surgeries due to their favorable tensile strength and ease of suturing. Despite concerns about infection risk, synthetic grafts remain the preferred option in most hospitals due to familiarity and availability.
Hybrid vascular grafts are the fastest-growing subsegment, reflecting a shift in surgical preferences toward biologically enhanced materials. Hybrid grafts are designed to promote endothelialization while maintaining structural integrity. For instance, a synthetic scaffold seeded with patient-derived cells offers reduced risk of rejection and improved healing. Academic centers and private biotech firms in the U.S. are collaborating to commercialize these grafts, supported by clinical trials focused on small-diameter applications, which have historically been prone to failure.
Country-Level Analysis
In the U.S., vascular graft utilization is highly influenced by regional healthcare accessibility, demographic distribution, and specialization of medical centers. Major urban hospitals in states like California, New York, and Texas lead in the adoption of advanced grafts and minimally invasive procedures. Institutions such as the Cleveland Clinic and Mayo Clinic are at the forefront of cardiovascular innovation, frequently partnering with medical device firms to conduct clinical evaluations of new graft technologies.
On the policy front, Medicare and Medicaid reimbursement plays a significant role in patient access to vascular procedures. Positive reimbursement codes for CABG, hemodialysis access, and aneurysm repair surgeries have encouraged more providers to offer advanced graft options. Furthermore, the presence of a well-established transplant and cardiovascular surgery infrastructure ensures early adoption of biologic and hybrid graft innovations.
Community hospitals and ambulatory surgical centers are also expanding vascular surgery services, fueled by rising demand and training availability. The increased focus on outpatient vascular interventions, particularly with endovascular stent grafts, is expected to deepen market penetration across non-metropolitan areas.
Recent Developments
March 2025 – W. L. Gore & Associates received expanded FDA clearance for their hybrid vascular graft for small-diameter vessel applications, following successful trials across U.S. hospitals.
January 2025 – Getinge AB announced a strategic collaboration with the University of Michigan to develop biologically-enhanced synthetic grafts designed for improved patency in diabetic patients.
November 2024 – Terumo Cardiovascular Systems introduced a new line of polyester vascular grafts optimized for minimally invasive CABG, with early adoption reported in Florida and Illinois.
August 2024 – LeMaitre Vascular acquired a U.S.-based startup specializing in decellularized allografts, aiming to expand its biological graft portfolio in North America.
June 2024 – BD (Becton, Dickinson and Company) launched a next-generation hemodialysis access graft featuring antimicrobial coating and improved kink resistance.
Key U.S. Vascular Grafts Company Insights
Medtronic, Terumo Corporation, BD, and Abbott are some of the prominent companies in U.S. vascular grafts market. These key players are identified based on their product portfolios, revenues, collaborations, and other strategic initiatives adopted by them.
The increasing use of vascular grafts in primary heart care is expected to boost the regional market. Key players are investing and expanding their businesses in the region, boosting regional market growth. This is attributed to several factors, such as increased adoption of such devices, rising technological advancements, and increased product launches by the key players operating in the market.
Key U.S. Vascular Grafts Companies:
Medtronic
Terumo Corporation
LeMaitre Vascular, Inc.
Getinge AB
BD (Becton Dickinson)
Abbott
B. Braun Melsungen AG.
Abbott
W. L. Gore and Associates, Inc.
MicroPort Scientific Corporation
Endologix
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Vascular Grafts market.
By Product
Hemodialysis Access Grafts
Endovascular Stent Grafts
Coronary Artery By-Pass Grafts
Vascular Grafts for Aorta Disease
Peripheral Vascular Grafts
By Application
Cardiac Aneurysm
Endovascular Stent Graft
Vascular Graft
Kidney Failure
Vascular Occlusion
Coronary Artery Disease
By Raw Material
Synthetic Vascular Grafts
Polytetrafluoroethylene (PTFE) Grafts
Polyester Grafts
Polyurethane Grafts
Biological Vascular Grafts
Autografts
Allografts
Xenografts
Hybrid Vascular Grafts
Key Takeaways:
The cardiac aneurysm market led the vascular grafts market with a revenue share of 51.9% in 2023.
The vascular occlusion segment is expected to witness the highest growth over the forecast period.
The polytetrafluoroethylene (PTFE) vascular grafts segment led the vascular grafts market with a revenue share of 45.12% in 2023.
The polyester vascular grafts segment is expected to witness considerable growth over the forecast period.
The endovascular stent grafts segment led the vascular grafts market with a revenue share of 64.27% in 2023.
The peripheral vascular grafts segment is expected to witness considerable growth over the forecast period.
Market Overview
The U.S. vascular grafts market has evolved into a vital pillar of cardiovascular and renal health care, underpinned by the rising prevalence of chronic diseases such as peripheral artery disease, coronary artery disease, and end-stage renal disease. A vascular graft is a medical device surgically implanted to replace, bypass, or repair blood vessels that are damaged or blocked. These devices are essential for ensuring adequate blood flow in patients where native blood vessels are no longer viable.
In the United States, cardiovascular diseases remain the leading cause of death, and a significant percentage of the population is either undergoing or at risk of requiring vascular surgeries. Concurrently, the increase in the aging population, high rates of obesity, diabetes, and sedentary lifestyles contribute to arterial degradation and increased incidences of aneurysms, occlusions, and renal dysfunction. The market also benefits from the country's highly developed healthcare infrastructure, innovation ecosystem, and favorable reimbursement policies.
Technological advancements in graft materials and surgical techniques have led to more minimally invasive options and better outcomes. Furthermore, the growing number of end-stage renal disease (ESRD) patients requiring hemodialysis access grafts has significantly propelled the demand for vascular grafts in nephrology. Leading manufacturers are increasingly focusing on hybrid and biologically engineered grafts that offer higher biocompatibility and longer patency, addressing longstanding concerns with infection and thrombosis.
Major Trends in the Market
Rising Adoption of Endovascular Stent Grafts: Minimally invasive endovascular aneurysm repair (EVAR) procedures are gaining popularity over traditional open surgeries.
Development of Biocompatible Hybrid Grafts: The industry is witnessing innovation in combining synthetic and biological elements for enhanced performance.
Increase in Hemodialysis Access Graft Demand: A growing population of chronic kidney disease (CKD) patients is driving demand for reliable vascular access devices.
Personalized and 3D-Printed Grafts: Precision medicine is influencing vascular graft design, with customized sizes and configurations becoming more feasible.
FDA Fast-Tracking Novel Graft Approvals: Regulatory bodies are expediting the approval of life-saving devices under breakthrough device designations.
Graft Integration with Drug-Eluting Technologies: Drug-coated grafts that minimize restenosis and thrombosis are emerging in clinical trials.
U.S. Vascular Grafts Market Report Scope
Report Attribute
Details
Market Size in 2024
USD 740.07 million
Market Size by 2033
USD 1,349.18 million
Growth Rate From 2024 to 2033
CAGR of 6.9%
Base Year
2023
Forecast Period
2024 to 2033
Segments Covered
Product, Application, Raw Material
Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)
Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled
Medtronic, Terumo Corporation, LeMaitre Vascular, Inc., Getinge AB, BD (Becton Dickinson), Abbott, B. Braun Melsungen AG., W. L. Gore and Associates, Inc., MicroPort Scientific Corporation, Endologix
Key Market Driver: High Prevalence of Cardiovascular and Renal Diseases
A fundamental driver for the U.S. vascular grafts market is the consistently high burden of cardiovascular and renal diseases across the population. According to the CDC, nearly 20 million Americans suffer from coronary artery disease, and over 800,000 Americans experience a heart attack annually. Vascular grafts are indispensable in managing these conditions, particularly when native blood vessels are no longer suitable for surgical use.
Simultaneously, over 786,000 Americans live with ESRD, many of whom undergo hemodialysis several times a week. For these patients, reliable access grafts are critical to sustaining life. The increasing incidence of risk factors such as hypertension, diabetes, and high cholesterol has contributed to the growing need for vascular intervention. As more individuals progress to stages requiring surgical solutions, the demand for vascular grafts across cardiovascular and renal applications continues to escalate.
Key Market Restraint: Risk of Graft-Related Infections and Complications
Despite technological innovations, the U.S. vascular grafts market faces challenges related to post-operative complications, particularly infections and graft thrombosis. Synthetic grafts, especially those used in long-term applications like hemodialysis access, are prone to bacterial colonization, leading to systemic infections and graft failure. These complications not only increase patient morbidity but also result in costly revisions or emergency interventions.
Additionally, mismatch in graft elasticity, improper healing, and immune reactions can contribute to limited patency rates, particularly in small-diameter grafts. While biological and hybrid grafts offer improved outcomes, they come with higher costs and logistical challenges in sourcing and storage. Concerns around long-term durability and performance in biologically engineered grafts have also posed caution among healthcare providers.
Key Market Opportunity: Biologically Engineered and Hybrid Vascular Grafts
As the industry shifts toward personalized medicine and biocompatibility, a major opportunity lies in the development and commercial expansion of biologically engineered and hybrid vascular grafts. These grafts aim to combine the strength and structure of synthetic materials with the healing potential and adaptability of biological tissues. For example, a graft composed of PTFE coated with autologous endothelial cells can reduce rejection rates and improve long-term patency.
Such next-generation grafts are also more suitable for younger patients or those requiring long-term implantation, as they adapt better to physiological conditions. Research collaborations between biotech companies and academic medical centers are driving innovation in this space. Companies focusing on tissue regeneration and stem cell applications are now entering the vascular graft market with promising solutions poised for FDA approvals.
Segments Insights:
By Product
Endovascular stent grafts dominated the U.S. vascular grafts market in 2024, primarily due to the growing preference for minimally invasive procedures. Endovascular aneurysm repair (EVAR) using stent grafts has revolutionized how abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) are treated. With less operative trauma, shorter hospital stays, and quicker recovery, stent grafts are increasingly chosen over open repair surgeries. Top-tier hospitals in the U.S. are now offering EVAR as a standard of care, particularly for older patients who are poor candidates for open surgery.
Hemodialysis access grafts are the fastest growing product segment, driven by the surge in ESRD patients requiring vascular access. Synthetic grafts, especially those made from PTFE, are widely used when autologous access is not feasible. Companies have also introduced self-sealing grafts and antimicrobial-coated variants to reduce complications. In 2024, multiple regional dialysis centers in the U.S. reported rising demand for graft placement surgeries, highlighting the need for durable and infection-resistant solutions.
By Application
Coronary artery disease (CAD) represented the dominant application segment, as coronary artery bypass grafting (CABG) remains a common surgical intervention for severe blockages. Vascular grafts are used to reroute blood flow around narrowed arteries, ensuring sufficient myocardial perfusion. The U.S. performs over 300,000 CABG procedures annually, making vascular grafts an integral part of cardiovascular surgery. The preference for synthetic and autograft options continues to vary based on patient profile and surgeon expertise.
Meanwhile, vascular occlusion is expected to be the fastest growing segment, attributed to the rising cases of peripheral artery disease (PAD), especially among diabetic and elderly populations. PAD results in poor limb perfusion, often requiring bypass grafts to avoid amputations. Hospitals across the Midwest and Southern U.S. have reported increased PAD-related surgeries, further expanding the market for lower limb vascular grafts and novel hybrid solutions that minimize thrombogenicity.
By Raw Material
Synthetic vascular grafts dominate the U.S. market, largely because of their long-standing use, reliability, and cost-effectiveness. Among these, PTFE grafts are most commonly used due to their non-thrombogenic surface and mechanical durability. They are standard in hemodialysis access, peripheral vascular repair, and certain cardiac procedures. Polyester grafts are also used widely in aortic surgeries due to their favorable tensile strength and ease of suturing. Despite concerns about infection risk, synthetic grafts remain the preferred option in most hospitals due to familiarity and availability.
Hybrid vascular grafts are the fastest-growing subsegment, reflecting a shift in surgical preferences toward biologically enhanced materials. Hybrid grafts are designed to promote endothelialization while maintaining structural integrity. For instance, a synthetic scaffold seeded with patient-derived cells offers reduced risk of rejection and improved healing. Academic centers and private biotech firms in the U.S. are collaborating to commercialize these grafts, supported by clinical trials focused on small-diameter applications, which have historically been prone to failure.
Country-Level Analysis
In the U.S., vascular graft utilization is highly influenced by regional healthcare accessibility, demographic distribution, and specialization of medical centers. Major urban hospitals in states like California, New York, and Texas lead in the adoption of advanced grafts and minimally invasive procedures. Institutions such as the Cleveland Clinic and Mayo Clinic are at the forefront of cardiovascular innovation, frequently partnering with medical device firms to conduct clinical evaluations of new graft technologies.
On the policy front, Medicare and Medicaid reimbursement plays a significant role in patient access to vascular procedures. Positive reimbursement codes for CABG, hemodialysis access, and aneurysm repair surgeries have encouraged more providers to offer advanced graft options. Furthermore, the presence of a well-established transplant and cardiovascular surgery infrastructure ensures early adoption of biologic and hybrid graft innovations.
Community hospitals and ambulatory surgical centers are also expanding vascular surgery services, fueled by rising demand and training availability. The increased focus on outpatient vascular interventions, particularly with endovascular stent grafts, is expected to deepen market penetration across non-metropolitan areas.
Recent Developments
March 2025 – W. L. Gore & Associates received expanded FDA clearance for their hybrid vascular graft for small-diameter vessel applications, following successful trials across U.S. hospitals.
January 2025 – Getinge AB announced a strategic collaboration with the University of Michigan to develop biologically-enhanced synthetic grafts designed for improved patency in diabetic patients.
November 2024 – Terumo Cardiovascular Systems introduced a new line of polyester vascular grafts optimized for minimally invasive CABG, with early adoption reported in Florida and Illinois.
August 2024 – LeMaitre Vascular acquired a U.S.-based startup specializing in decellularized allografts, aiming to expand its biological graft portfolio in North America.
June 2024 – BD (Becton, Dickinson and Company) launched a next-generation hemodialysis access graft featuring antimicrobial coating and improved kink resistance.
Key U.S. Vascular Grafts Company Insights
Medtronic, Terumo Corporation, BD, and Abbott are some of the prominent companies in U.S. vascular grafts market. These key players are identified based on their product portfolios, revenues, collaborations, and other strategic initiatives adopted by them.
The increasing use of vascular grafts in primary heart care is expected to boost the regional market. Key players are investing and expanding their businesses in the region, boosting regional market growth. This is attributed to several factors, such as increased adoption of such devices, rising technological advancements, and increased product launches by the key players operating in the market.
Key U.S. Vascular Grafts Companies:
Medtronic
Terumo Corporation
LeMaitre Vascular, Inc.
Getinge AB
BD (Becton Dickinson)
Abbott
B. Braun Melsungen AG.
Abbott
W. L. Gore and Associates, Inc.
MicroPort Scientific Corporation
Endologix
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Vascular Grafts market.
By Product
Hemodialysis Access Grafts
Endovascular Stent Grafts
Coronary Artery By-Pass Grafts
Vascular Grafts for Aorta Disease
Peripheral Vascular Grafts
By Application
Cardiac Aneurysm
Endovascular Stent Graft
Vascular Graft
Kidney Failure
Vascular Occlusion
Coronary Artery Disease
By Raw Material
Synthetic Vascular Grafts
Polytetrafluoroethylene (PTFE) Grafts
Polyester Grafts
Polyurethane Grafts
Biological Vascular Grafts
Autografts
Allografts
Xenografts
Hybrid Vascular Grafts
Table of Contents
707 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
